The purpose of this retrospective chart review study was to review the nature and clinical course of benign and malignant submandibular gland tumors at 2 major university-affiliated tertiary medical centers. All patients who underwent submandibular salivary gland excision between 1990 and 2010 were included. Clinical and disease-related data were collected from the medical charts. One hundred ninety-three patients were identified, of whom 108 (56%) had non-neoplastic disorders (sialolithiasis and sialadenitis). The remaining 85 patients (44%) had a submandibular salivary gland tumor. The most common benign neoplasm was pleomorphic adenoma (53 patients). Twenty tumors (24%) were malignant: adenoid cystic carcinoma in 11 patients, mucoepidermoid carcinoma in 6 patients, and adenocarcinoma in 3 patients. Recurrence was noted in 7 patients with submandibular gland malignancy and in 2 patients with pleomorphic adenoma. The 5-year disease-free survival rate was 63%. Tumors of the submandibular gland are infrequently malignant. Recurrent submandibular salivary gland pleomorphic adenoma is rare compared with recurrences in the parotid gland.
Introduction
Salivary gland tumors are rare, comprising 10% of all head and neck neoplasms. 1 Among submandibular salivary gland tumors, the proportion of malignancies approaches 50%, which is a higher proportion than in the parotid gland. 2, 3 The predominant types of salivary gland malignancies are mucoepidermoid carcinoma, adenoid cystic carcinoma, and adenocarcinoma. 4 The diagnosis of submandibular gland neoplasms is made by ultrasonography, computed tomography, or magnetic resonance imaging together with fine-needle aspiration biopsy. In some cases, the submandibular gland is excised for diagnostic purposes. 5 Excision of the submandibular gland is the treatment of choice for both neoplastic and non-neoplastic disorders that cannot be controlled with conservative (medical) measures. The surgical approach may be cervical, intraoral, or endoscopic. 6 Prompt treatment of submandibular gland malignancies is important because of their relatively aggressive behavior and the proximity of the gland to adjacent vital structures. 7 Given the high incidence of aggressive variants and the high rate of locoregional recurrence of submandibular gland malignancies, researchers have suggested that adjuvant radiation should be considered in advanced disease and in high-risk patients to improve locoregional control. 8, 9 These findings also have been supported by those from recent large studies. 10, 11 Nodal disease, tumor stage, and perineural invasion have been found to be the most important predictors of outcome that significantly decrease the rate of survival. [12] [13] [14] Other predictive factors reported to date are patient age, tumor histopathologic type, facial nerve involvement, extraglandular tumor extension, and tumor grade. 15 The purpose of the present study was to review the nature and clinical course of submandibular salivary gland tumors. 
Patients and methods
The registry of two major tertiary university-affiliated hospitals was reviewed for all patients who underwent submandibular gland excision from 1990 to 2010. The findings were then cross-referenced with a head and neck surgical oncology registry. Inclusion and exclusion criteria. Patients with newly diagnosed, previously untreated, and pathologically confirmed disease were included in the study. Exclusion criteria were patient refusal of treatment, missing data, and follow-up of less than 1 year.
Evaluation. In all cases, the pathologic assessment was performed by a head and neck pathologist. Tumors were staged at the time of diagnosis according to the American Joint Committee on Cancer (TNM) classification system for the given time period. For purposes of the study, the following data were collected from the medical charts: patient age and sex, clinical parameters, pathology studies, treatment, complications, and follow-up.
Statistical analysis. Differences in mean continuous variables between groups were analyzed by the Student t test and differences in categorical variables by the Fisher exact test. Rates of disease-specific survival and disease-free survival, calculated from the date of diagnosis to the date of death or recurrence or last follow-up, were analyzed by the Kaplan-Meier method.
The study was approved by the Institutional Review Board.
Results

Clinical and demographic features.
A total of 193 patients underwent submandibular gland excision during the study period; 108 (56%) had a non-neoplastic disorder (sialolithiasis or chronic sialadenitis). The remaining 85 (44%) had a submandibular tumor. Characteristics of the 85 patients with submandibular tumors are presented in table 1.
Pathology. Sixty-five patients (76%) had a benign tumor and 20 (24%) had a malignant tumor. Mean age of these respective subgroups was 55.4 years and 60.5 years. The most common benign neoplasm was pleomorphic adenoma (n = 53), followed by benign lymphoepithelial lesion (n = 8) and oncocytoma (n = 4). The malignant tumors consisted of adenoid cystic carcinoma (n = 11), mucoepidermoid carcinoma (n = 6), and adenocarcinoma (n = 3). Pathologic distribution is presented in table 2.
Five patients with malignant tumors had clinical and/ or radiographic evidence of regional nodal metastases at presentation. The mean duration of follow-up was 6.5 years (range: 2 to 20 years).
Treatment. Patients with malignant tumors underwent concomitant ipsilateral selective neck dissection at levels 1 to 3. Modified radical neck dissection was performed in 1 patient. In 1 patient with a high-grade mucoepidermoid carcinoma, a marginal mandibulectomy was required to completely excise the tumor. Four patients (4.7%) had transient marginal mandibular nerve paresis after surgery. There were no cases of postoperative surgical wound infection.
Seventeen patients with malignant disease were treated with adjuvant radiation, and 1 patient with highgrade mucoepidermoid carcinoma received adjuvant chemoradiotherapy.
Recurrence and survival. Recurrence was documented in 2 of the 53 patients (3.8%) with pleomorphic adenoma and in 7 of the 20 patients (35%) with malignant tumors. In the group with malignant tumors, regional recurrence was diagnosed in 5 patients and distant recurrence in 2. The mean time to recurrence from surgery was 9 months (range: 6 to 13 months). The disease-free survival rate at 5 years was 63%. Five patients were alive with disease at their last follow-up. Three patients died of the disease and 1 died of other causes. The 5-year overall survival rate was 52%. In 15 SUBMANDIBULAR SALIVARY GLAND TUMORS: CLINICAL COURSE AND OUTCOME OF A 20-YEAR MULTICENTER STUDY of the 20 patients with malignant tumors, perineural and/or lymphovascular invasion was noted but did not correlate with recurrence or survival.
Discussion
In the present study, 24% of all submandibular neoplasms treated over a 20-year period were malignant, which is a much lower proportion than previously reported 1-3 and resembles the frequency of malignant tumors in the parotid gland.
Malignant neoplasms were associated with a relatively high recurrence rate, with a 5-year disease-free survival rate of 63% following surgery and radiation. A recent retrospective study of 74 malignant submandibular gland tumors reported a lower local recurrence rate in patients treated by surgery and radiation than by surgery alone. 16 Although the difference was not statistically significant, the authors speculated that radiotherapy was probably beneficial.
Among patients with benign tumors, only 2 patients with a pleomorphic adenoma had a recurrence and were treated with additional surgery. These data suggest a low recurrence rate for benign submandibular tumors as opposed to the rate of recurrence in the parotid gland, but we were unable to find precise data in the medical literature to support these findings. One study reported a higher rate of recurrence of benign neoplasms in the parotid gland compared with the submandibular gland. 2 To explain this difference, we speculate that the submandibular gland is more amenable to complete excision than is the parotid because there is no need to resect tissue adjacent to the facial nerve during surgery. Moreover, the surgical difficulty of complete resection of deep lobe parotid tumors does not exist in the submandibular gland.
Evaluation of the neck is essential in all cases of submandibular malignancy. Mallik et al recommended elective neck dissection for patients with all stages of malignant submandibular tumors except T1. 17 In our study, all but 1 patient with a malignant submandibular tumor underwent neck dissection. Given the tendency for locoregional recurrence of malignant submandibular tumors, we believe that comprehensive resection should be performed for all but low-grade mucoepidermoid tumors.
Overall 5-year survival in our cohort was 52%. This rate is in accordance with that found in other studies. 18 Pinkston and Cole found that the incidence rate for both benign and malignant submandibular tumors increases until age 70 and then declines. 18 Crabtree and Yarington noted that younger patients tend to have benign tumors rather than malignancies. 19 However, our study yielded no correlation between age and tumor incidence. Previous reports have shown that several histopathologic features may predict poor outcome, including a cystic component of less than 20%, 4 or more mitotic figures per 10 high-power fields, neural involvement, necrosis, and anaplasia. [18] [19] [20] Interestingly, for tumors of equal histopathologic grade, the prognosis appeared to be better if the tumor was located in the parotid gland than in the submandibular gland. 21 In a large study on salivary gland tumors, Goode et al concluded that age, tumor size, and preoperative symptoms affected patient outcome. 12 In the present study, perineural and lymphovascular invasion did not correlate with either recurrence or survival.
In conclusion, our study shows that malignant disease is infrequent in tumors of the submandibular salivary gland. Patients with submandibular gland pleomorphic adenoma have a low risk of recurrence compared with that of the parotid gland.
